Off-label use of intravenous immunoglobulin for solid organ transplant rejection a review of clinical effectiveness
Intravenous immunoglobulin (IVIG) has been identified as a potentially beneficial therapy for patients experiencing solid organ transplant rejection. The purpose of this report is to provide a synthesis of the available evidence on the clinical effectiveness of off-label use of IVIG for solid organ...
| Main Authors: | , |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
2018, April 30, 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Intravenous immunoglobulin (IVIG) has been identified as a potentially beneficial therapy for patients experiencing solid organ transplant rejection. The purpose of this report is to provide a synthesis of the available evidence on the clinical effectiveness of off-label use of IVIG for solid organ transplant rejection. This report is complementary to a 2017 CADTH Rapid Response, Summary of Abstracts report: "Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection, Paraneoplastic Disorders, or Recurrent Miscarriage: Clinical Effectiveness" |
|---|---|
| Item Description: | "Rapid Response Service." |
| Physical Description: | 1 PDF file (19 pages) illustration |